Cambridge, United Kingdom

Brian A Callingham

This inventor holds 2 USPTO granted patents. Top assignee: National Research Development Corporation. Active years: 1991-1993.


% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 2

Forward Citations = 37(Granted Patents)


Company Filing History:


Years Active: 1991-1993

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Brian A Callingham: Innovator in Pharmaceutical Compositions

Introduction

Brian A Callingham is a notable inventor based in Cambridge, GB. He has made significant contributions to the field of pharmaceutical compositions, particularly in the treatment of iron deficiency anemia. With a total of two patents to his name, Callingham's work is recognized for its innovative approach to iron complexes.

Latest Patents

Callingham's latest patents include groundbreaking pharmaceutical compositions. One patent focuses on iron complexes comprising a ferric cation in combination with at least two different ligands. Another patent addresses pharmaceutical compositions for the buccal or nasal administration of a neutral 3:1 hydroxypyrone:iron(III) complex of 3-hydroxy-4-pyrone. These compositions are valuable for treating iron deficiency anemia.

Career Highlights

Throughout his career, Callingham has been associated with the National Research Development Corporation. His work has contributed to advancements in pharmaceutical science, particularly in the development of effective treatments for iron deficiency.

Collaborations

Callingham has collaborated with esteemed colleagues such as Robert Charles Hider and George Kontoghiorghes. These partnerships have further enhanced the impact of his research and innovations in the field.

Conclusion

Brian A Callingham stands out as an influential inventor in the pharmaceutical industry. His innovative patents and collaborations have significantly advanced the treatment of iron deficiency anemia.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…